Catalent Inc (NASDAQ:CTLT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Friday.

According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “

CTLT has been the topic of a number of other research reports. BidaskClub upgraded shares of Catalent from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. Wells Fargo & Company boosted their price objective on shares of Catalent from $39.00 to $43.00 and gave the stock an “outperform” rating in a report on Wednesday, September 20th. Bank of America Corporation reiterated a “buy” rating and issued a $45.00 price objective (up previously from $40.00) on shares of Catalent in a report on Wednesday, September 20th. Piper Jaffray Companies reiterated a “buy” rating and issued a $45.00 price objective on shares of Catalent in a report on Tuesday, August 29th. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $38.00 price objective (up previously from $35.00) on shares of Catalent in a report on Tuesday, August 29th. Five equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Catalent currently has an average rating of “Buy” and an average price target of $41.67.

Shares of Catalent (CTLT) traded up $0.70 during mid-day trading on Friday, reaching $42.70. 910,929 shares of the company’s stock were exchanged.

Catalent (NASDAQ:CTLT) last issued its quarterly earnings data on Monday, August 28th. The company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.08. Catalent had a net margin of 10.02% and a return on equity of 36.29%. The firm had revenue of $616.90 million for the quarter, compared to analyst estimates of $547.48 million. During the same quarter in the previous year, the business posted $0.52 EPS. The firm’s revenue was up 15.9% compared to the same quarter last year.

ILLEGAL ACTIVITY WARNING: “Catalent Inc (CTLT) Downgraded by Zacks Investment Research” was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/catalent-inc-ctlt-downgraded-by-zacks-investment-research/1676599.html.

In other news, SVP Christine Dolan sold 1,594 shares of the company’s stock in a transaction dated Tuesday, August 29th. The shares were sold at an average price of $38.75, for a total value of $61,767.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Institutional investors have recently modified their holdings of the company. State of Wisconsin Investment Board acquired a new stake in shares of Catalent in the 2nd quarter valued at about $3,334,000. Chicago Equity Partners LLC grew its position in shares of Catalent by 20.4% during the 2nd quarter. Chicago Equity Partners LLC now owns 109,825 shares of the company’s stock valued at $3,855,000 after buying an additional 18,600 shares during the last quarter. Airain ltd bought a new stake in shares of Catalent during the 2nd quarter valued at about $3,524,000. Sei Investments Co. grew its position in shares of Catalent by 79,537.0% during the 2nd quarter. Sei Investments Co. now owns 43,004 shares of the company’s stock valued at $1,509,000 after buying an additional 42,950 shares during the last quarter. Finally, Seven Eight Capital LP bought a new stake in shares of Catalent during the 2nd quarter valued at about $2,685,000.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Analyst Recommendations for Catalent (NASDAQ:CTLT)

Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.